Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?


OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary


Protagonist Therapeutics is owned by 120.15% institutional investors, 0.71% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.38% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.57% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics120.15%0.71%-20.87%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.78M15.38%$1.03B
Farallon capital management6.35M9.99%$669.17M
Blackrock5.76M9.39%$199.52M
Vanguard group5.41M8.49%$472.83M
Ubs group5.18M8.14%$545.74M
Rtw investments, lp5.06M7.96%$533.22M
Wellington management group llp3.60M5.66%$379.40M
State street3.12M4.90%$328.51M
Janus henderson group2.89M4.55%$304.87M
Bvf inc/il2.56M4.03%$170.12M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M39.57%$258.14M
Lynx1 capital management lp700.01K9.47%$46.50M
Aquilo capital management81.69K7.08%$3.95M
Bvf inc/il2.56M6.90%$170.12M
Adar1 capital management989.18K6.17%$65.71M
Rtw investments, lp5.06M5.31%$533.22M
Nationale-nederlanden powszechne towarzystwo emerytalne571.83K5.11%$60.27M
Knott david m jr63.00K3.95%$6.64M
Farallon capital management6.35M3.81%$669.17M
Eagle health investments lp179.32K3.31%$18.90M

Top Buyers

HolderShares% AssetsChange
Ubs group5.18M0.08%2.41M
Vanguard group5.41M0.01%1.16M
Hood river capital management829.28K0.88%829.28K
Jennison associates1.07M0.08%740.85K
Invesco2.16M0.03%596.83K

Top Sellers

HolderShares% AssetsChange
Pacer advisors---1.88M
Deep track capital, lp---1.72M
Fairmount funds management---931.89K
Bvf inc/il2.56M6.90%-650.13K
Commodore capital lp---450.00K

New Positions

HolderShares% AssetsChangeValue
Hood river capital management829.28K0.88%829.28K$87.41M
Rubric capital management lp428.00K0.48%428.00K$45.11M
Vanguard fiduciary trust412.73K0.01%412.73K$43.50M
Eagle asset management357.63K0.07%357.63K$12.59M
Vestal point capital, lp326.16K0.96%326.16K$34.38M

Sold Out

HolderChange
Tfc financial management-1.00
Td capital management-4.00
Ifp advisors-5.00
Mendota financial group-6.00
Flagship harbor advisors-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026324-1.82%76,383,7468.00%1200.98%163-11.41%1052.94%
Dec 31, 2025156-44.68%26,213,291-62.92%410.33%90-30.23%45-58.33%
Sep 30, 2025140-48.91%21,573,409-68.80%330.29%55-67.26%60-20.00%
Jun 30, 2025279-3.79%70,876,6488.54%1111.04%1673.73%78-13.33%
Mar 31, 202519-92.31%15,761,655-75.08%250.24%12-91.18%5-93.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.58M5.57%753.00
Vanguard Total Stock Mkt Idx Inv2.04M3.18%5.86K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
Vanguard Health Care Inv1.56M2.42%495.12K
Vanguard Small Cap Index1.47M2.29%-2.92K
iShares Russell 2000 ETF1.37M2.13%11.56K
T. Rowe Price Health Sciences1.16M1.82%250.56K
SPDR® S&P Biotech ETF983.05K1.58%2.19K
State Street® SPDR® S&P® Biotech ETF979.02K1.52%-9.68K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 10, 2026Waddill William D.-Sell$969.12K
May 29, 2026Waddill William D.-Sell$896.76K
May 12, 2026PATEL DINESH V PH D President and CEOSell$7.51M
May 07, 2026Giraudo Bryan-Sell$3.61M
May 08, 2026Giraudo Bryan-Sell$513.00K

Insider Transactions Trends


DateBuySell
2026 Q2-8
2026 Q1-18
2025 Q4-3
2025 Q3-6
2025 Q2-3

PTGX Ownership FAQ


Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 120.15%, followed by 0.71% insiders and -20.86% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 35.75%, which Protagonist Therapeutics exceeds.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.78M shares, 15.38%), Farallon capital management (6.35M shares, 9.99%), and Blackrock (5.76M shares, 9.39%). Together, they hold 34.76% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 39.57% of its assets in 2.45M Protagonist Therapeutics shares, valued at 258.14M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 5.57% of its total shares outstanding invested in 3.58M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools